Search results
Alto Neuroscience share maintains Outperform on ALTO-101 phase 2 trial By Investing.com
Investing.com· 17 hours agoOn Thursday, Baird reaffirmed its Outperform rating on Alto Neuroscience (NYSE:ANRO), with a steady...
Brain Canada Launches $26 Million Platform Support Grants (PSG) Program to Accelerate Neuroscience...
Digital Journal· 21 hours agoPlatform Support Grants Program Overview The PSG program supports major research platforms at a...
A study identified 6 types of depression. Here’s why that matters
CNN via Yahoo News· 20 hours ago“It needs to be thought of as a very preliminary study that needs to be replicated.” Additionally,...
Food hoarding is a problem. Here is what you need to know
CNN via Yahoo News· 2 hours agoA stockpile of cans, a stash of food in a closet, and an inability to throw food away once it has...
After 4 rounds of chemotherapy, Isabella Strahan rings the bell
Good Morning America via Yahoo News· 4 days agoIsabella Strahan, the daughter of "Good Morning America" co-anchor Michael Strahan, is celebrating a...
Want to live a longer, healthier life? New research sheds light on the lifestyle factors that...
Yahoo Life· 19 hours agoHow can you live a longer life? There were a few major factors that emerged as helping participants...
How a healthy lifestyle after age 80 can help you live to be 100
MedicalNewsToday via AOL· 1 day agoThose scoring in the 0 to 2 range lived the shortest amount of time. The team said in a release that...
Takeda flunks pivotal epilepsy tests but mulls path to market for Ovid-partnered prospect
FierceBiotech· 4 days agoTakeda’s late-phase epilepsy program has failed a key test, chalking up misses on the primary endpoints in pivotal trials in two indications. The drug candidate, the cholesterol 24 hydroxylase ...
Magic Mushrooms and the Mind: Psilocybin’s Hyperconnected Brain State Linked to Therapeutic Effects
SciTechDaily· 5 days agoStudy shows psilocybin induces dynamic brain connectivity, linked to profound, ego-altering...
Takeda’s epilepsy drug misses the mark in two Phase III trials
Clinical Trials Arena via Yahoo Finance· 4 days agoHead of the neuroscience unit at Takeda, Sarah Sheikh, said that the company will be engaging with...